[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 27 of about 27
1. Skubitz KM, Pambuccian S, Manivel JC, Skubitz AP: Identification of heterogeneity among soft tissue sarcomas by gene expression profiles from different tumors. J Transl Med; 2008 May 06;6:23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of heterogeneity among soft tissue sarcomas by gene expression profiles from different tumors.
  • The heterogeneity that soft tissue sarcomas (STS) exhibit in their clinical behavior, even within histological subtypes, complicates patient care.
  • Morphologic features are generally good predictors of biologic behavior, however, metastatic propensity, tumor growth, and response to chemotherapy may be determined by gene expression patterns that do not correlate well with morphology.
  • One approach to identify heterogeneity is to search for genetic markers that correlate with differences in tumor behavior.
  • We have reported gene expression patterns that distinguish two subgroups of clear cell renal carcinoma (ccRCC), and other gene expression patterns that distinguish heterogeneity of serous ovarian carcinoma (OVCA) and aggressive fibromatosis (AF).
  • In addition, several genes that are targets of some anti-tumor drugs were found to be differentially expressed in particular subsets of STS.

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1984 Feb 1;53(3):530-41 [6692258.001]
  • [Cites] J Lab Clin Med. 2004 Aug;144(2):78-91 [15322502.001]
  • [Cites] Cancer. 1986 Jul 15;58(2):306-9 [3719523.001]
  • [Cites] Cancer. 1988 Feb 15;61(4):817-23 [3338039.001]
  • [Cites] Cancer. 1988 Sep 1;62(5):994-8 [3409180.001]
  • [Cites] Am J Physiol. 1992 Dec;263(6 Pt 1):L627-33 [1476204.001]
  • [Cites] Ann N Y Acad Sci. 1992 Dec 4;667:101-11 [1309029.001]
  • [Cites] Mod Pathol. 1995 Sep;8(7):705-10 [8539226.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):350-62 [8996162.001]
  • [Cites] Am J Pathol. 1997 Aug;151(2):329-34 [9250146.001]
  • [Cites] J Surg Oncol. 1999 Oct;72(2):77-82 [10518103.001]
  • [Cites] Cancer Immun. 2005 Feb 1;5:2 [15683221.001]
  • [Cites] Cancer Invest. 2005;23(2):105-18 [15813502.001]
  • [Cites] N Engl J Med. 2005 Aug 18;353(7):701-11 [16107623.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9226-35 [16230383.001]
  • [Cites] Histopathology. 2006 Jan;48(1):22-31 [16359534.001]
  • [Cites] Histopathology. 2006 Jan;48(1):51-62 [16359537.001]
  • [Cites] J Clin Oncol. 2006 Mar 1;24(7):1195-203 [16505440.001]
  • [Cites] J Lab Clin Med. 2006 May;147(5):250-67 [16697773.001]
  • [Cites] Transl Res. 2006 Nov;148(5):223-48 [17145569.001]
  • [Cites] J Natl Compr Canc Netw. 2007 Apr;5(4):364-99 [17442230.001]
  • [Cites] Mayo Clin Proc. 2007 Nov;82(11):1409-32 [17976362.001]
  • [Cites] Annu Rev Pathol. 2006;1:119-50 [18039110.001]
  • [Cites] Cancer Cell. 2007 Dec;12(6):514-27 [18068629.001]
  • [Cites] Oncogene. 1999 Nov 11;18(47):6615-20 [10597266.001]
  • [Cites] J Clin Pathol. 1999 Sep;52(9):695-6 [10655994.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Int J Cancer. 2001 Mar 20;95(2):102-7 [11241320.001]
  • [Cites] Nat Med. 2001 Jun;7(6):673-9 [11385503.001]
  • [Cites] Breast Cancer Res. 2001;3(6):365-72 [11737887.001]
  • [Cites] Lab Invest. 2002 Jan;82(1):97-103 [11796830.001]
  • [Cites] Hum Pathol. 2002 Jan;33(1):39-46 [11823972.001]
  • [Cites] Lancet. 2002 Apr 13;359(9314):1301-7 [11965276.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6973-8 [11983872.001]
  • [Cites] J Lab Clin Med. 2003 May;141(5):297-308 [12761473.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):1941-56 [12796356.001]
  • [Cites] Am J Pathol. 2003 Aug;163(2):691-700 [12875988.001]
  • [Cites] Cancer. 2003 Sep 1;98(5):1029-38 [12942572.001]
  • [Cites] J Lab Clin Med. 2004 Feb;143(2):89-98 [14966464.001]
  • [Cites] Clin Cancer Res. 2004 Jul 15;10(14):4776-83 [15269152.001]
  • [Cites] Cancer Immun. 2004 Aug 9;4:7 [15298487.001]
  • [Cites] J Clin Invest. 1985 Jan;75(1):11-8 [3965498.001]
  • (PMID = 18460215.001).
  • [ISSN] 1479-5876
  • [Journal-full-title] Journal of translational medicine
  • [ISO-abbreviation] J Transl Med
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA106878-03; United States / NCI NIH HHS / CA / R01 CA106878; United States / NCI NIH HHS / CA / R01 CA106878-03; United States / NCI NIH HHS / CA / R01CA106878
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Neoplasm
  • [Other-IDs] NLM/ PMC2412854
  •  go-up   go-down


2. Popadiuk CM, Xiong J, Wells MG, Andrews PG, Dankwa K, Hirasawa K, Lake BB, Kao KR: Antisense suppression of pygopus2 results in growth arrest of epithelial ovarian cancer. Clin Cancer Res; 2006 Apr 1;12(7 Pt 1):2216-23
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antisense suppression of pygopus2 results in growth arrest of epithelial ovarian cancer.
  • In epithelial ovarian cancer, constitutively active Wnt signaling is restricted to one (endometrioid) tumor subtype.
  • The purpose of this study was to determine the level of expression and growth requirements of human Pygopus2 (hPygo2) protein in epithelial ovarian cancer.
  • EXPERIMENTAL DESIGN: Expression and subcellular localization of hPygo2 was determined in epithelial ovarian cancer cell lines and tumors using Northern blot, immunoblot, and immunofluorescence.
  • Immunohistochemistry was done on 125 archived patient epithelial ovarian cancer tumors representing all epithelial ovarian cancer subtypes.
  • T-cell factor-dependent transcription levels were determined in epithelial ovarian cancer cells using TOPflash/FOPflash in vivo assays.
  • Phosphorothioated antisense oligonucleotides were transfected into cell lines and growth assayed by cell counting, anchorage-independent colony formation on soft agar, and xenografting into severe combined immunodeficient mice.
  • RESULTS: All six epithelial ovarian cancer cell lines and 82% of the patient samples overexpressed nuclear hPygo2 compared with control cells and benign disease.
  • Depletion of hPygo2 by antisense oligonucleotides in both Wnt-active (TOV-112D) and Wnt-inactive serous (OVCAR-3, SKOV-3) and clear cell (TOV-21G) carcinoma cell lines halted growth, assessed using tissue culture, anchorage-independent, and xenograft assays.
  • CONCLUSIONS: hPygo2 is unexpectedly widely expressed in, and required in the absence of, Wnt signaling for malignant growth of epithelial ovarian cancer, the deadliest gynecologic malignancy.
  • These findings strongly suggest that inhibition of hPygo2 may be of therapeutic benefit for treating this disease.
  • [MeSH-major] Intracellular Signaling Peptides and Proteins / drug effects. Neoplasms, Glandular and Epithelial / drug therapy. Oligodeoxyribonucleotides, Antisense / pharmacology. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Proliferation / drug effects. Disease Models, Animal. Drug Screening Assays, Antitumor. Female. Gene Expression Regulation, Neoplastic / drug effects. Gene Expression Regulation, Neoplastic / genetics. Humans. In Vitro Techniques. Mice. Neoplasms, Experimental / therapy. Structure-Activity Relationship. Transplantation, Heterologous. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16609037.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / Oligodeoxyribonucleotides, Antisense; 0 / PYGO2 protein, human
  •  go-up   go-down


3. Dalloul M, Sherer DM, Gorelick C, Serur E, Zinn H, Sanmugarajah J, Zigalo A, Abulafia O: Transient bilateral ovarian enlargement associated with large retroperitoneal lymphoma. Ultrasound Obstet Gynecol; 2007 Feb;29(2):236-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transient bilateral ovarian enlargement associated with large retroperitoneal lymphoma.
  • Bilateral ovarian enlargement may reflect benign or malignant processes of the ovary.
  • Benign causes of ovarian enlargement include luteomas, tumors such as mature cystic teratomas, fibrothecomas, cystadenomas and rare conditions including capillary hemangioma and massive edema of the ovaries.
  • Ovarian malignancies include epithelial, stromal and germ-cell tumors.
  • Primary malignancies that may exhibit metastases to the ovaries include gastrointestinal, breast and soft tissue tumors such as lymphoma.
  • We present an unusual case in which a patient presenting with weakness and mild lower abdominal and pelvic pain was noted at sonography to have bilaterally enlarged ovaries with features similar to those of massive ovarian edema as described previously, which has been associated with venous and lymphatic obstruction.
  • Subsequent computerized tomography (CT) imaging depicted a large retroperitoneal tumor, CT-guided biopsy of which revealed diffuse large B cell lymphoma.
  • The patient responded well to chemotherapy with significant shrinkage of the tumor, and reappearance of normal findings on ovarian sonography.
  • This case demonstrates that bilaterally enlarged ovaries may be the first clinical evidence of a large retroperitoneal tumor and that in such cases CT imaging may be warranted.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / pathology. Ovarian Neoplasms / pathology. Ovary / pathology. Retroperitoneal Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans. Hypertrophy / etiology. Hypertrophy / pathology. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 ISUOG. Published by John Wiley & Sons, Ltd.
  • (PMID = 17252529.001).
  • [ISSN] 0960-7692
  • [Journal-full-title] Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  • [ISO-abbreviation] Ultrasound Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


Advertisement
4. Germano G, Frapolli R, Simone M, Tavecchio M, Erba E, Pesce S, Pasqualini F, Grosso F, Sanfilippo R, Casali PG, Gronchi A, Virdis E, Tarantino E, Pilotti S, Greco A, Nebuloni M, Galmarini CM, Tercero JC, Mantovani A, D'Incalci M, Allavena P: Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res; 2010 Mar 15;70(6):2235-44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Inflammatory mediators present in the tumor milieu may promote cancer progression and are considered promising targets of novel biological therapies.
  • We previously reported that the marine antitumor agent trabectedin, approved in Europe in 2007 for soft tissue sarcomas and in 2009 for ovarian cancer, was able to downmodulate the production of selected cytokines/chemokines in immune cells.
  • The drug had marked antiproliferative effects on MLS cell lines at low nanomolar concentrations.
  • In vitro treatment with noncytotoxic concentrations of trabectedin selectively inhibited the production of CCL2, CXCL8, IL-6, VEGF, and PTX3 by MLS primary tumor cultures and/or cell lines.
  • A xenograft mouse model of human MLS showed marked reduction of CCL2, CXCL8, CD68+ infiltrating macrophages, CD31+ tumor vessels, and partial decrease of PTX3 after trabectedin treatment.
  • Similar findings were observed in a patient tumor sample excised after several cycles of therapy, indicating that the results observed in vitro might have in vivo relevance.
  • In conclusion, trabectedin has dual effects in liposarcoma: in addition to direct growth inhibition, it affects the tumor microenvironment by reducing the production of key inflammatory mediators.
  • [MeSH-major] Antineoplastic Agents, Alkylating / pharmacology. Dioxoles / pharmacology. Inflammation Mediators / metabolism. Liposarcoma, Myxoid / drug therapy. Tetrahydroisoquinolines / pharmacology
  • [MeSH-minor] Animals. Antigens, CD / biosynthesis. Antigens, CD / immunology. Antigens, Differentiation, Myelomonocytic / biosynthesis. Antigens, Differentiation, Myelomonocytic / immunology. C-Reactive Protein / biosynthesis. Cell Cycle / drug effects. Cell Death / drug effects. Cell Line, Tumor. Chemokine CCL2 / biosynthesis. Humans. Immunohistochemistry. Interleukin-6 / biosynthesis. Interleukin-8 / biosynthesis. Macrophages / immunology. Mice. Serum Amyloid P-Component / biosynthesis. Vascular Endothelial Growth Factor A / biosynthesis. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Liposarcoma.
  • Genetic Alliance. consumer health - Myxoid liposarcoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20215499.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Antineoplastic Agents, Alkylating; 0 / CD68 antigen, human; 0 / Chemokine CCL2; 0 / Dioxoles; 0 / Inflammation Mediators; 0 / Interleukin-6; 0 / Interleukin-8; 0 / Serum Amyloid P-Component; 0 / Tetrahydroisoquinolines; 0 / Vascular Endothelial Growth Factor A; 114899-77-3 / trabectedin; 148591-49-5 / PTX3 protein; 9007-41-4 / C-Reactive Protein
  •  go-up   go-down


5. Hummel T, Hord JD: Favorable response to soft tissue sarcoma therapy in an adolescent with embryonal renal sarcoma. Pediatr Blood Cancer; 2004 Jul;43(1):70-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Favorable response to soft tissue sarcoma therapy in an adolescent with embryonal renal sarcoma.
  • Embryonal renal sarcomas were first identified in 1995 among banked tumor samples originally classified as adult Wilms tumor.
  • Few long-term remissions were observed when these rare tumors were treated with chemotherapy usually used for childhood Wilms.
  • Data were collected from the medical record of an adolescent female with embryonal renal sarcoma and treated with sarcoma-directed chemotherapy and radiation.
  • At 66 months following diagnosis, the patient has no evidence of tumor but has experienced severe renal dysfunction and ovarian failure.
  • We believe there is a subset of patients with disseminated embryonal renal sarcoma that respond to intense sarcoma-directed therapy.
  • [MeSH-major] Kidney Neoplasms / therapy. Neoplasms, Germ Cell and Embryonal / therapy. Sarcoma / therapy
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans


6. Krawczuk-Rybak M, Leszczyńska E, Wysocka J, Zelazowska-Rutkowska B: [Anti-mullerian hormone in young women after chemotherapy and infradiaphragmatic radiotherapy for childhood cancer]. Pediatr Endocrinol Diabetes Metab; 2008;14(2):99-103
Hazardous Substances Data Bank. MENOTROPINS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anti-mullerian hormone in young women after chemotherapy and infradiaphragmatic radiotherapy for childhood cancer].
  • INTRODUCTION: Composed anticancer treatment leads to different late effects, such as ovarian failure, causing infertility or premature menopause.
  • AIM OF THE STUDY: was to analyse ovarian function, particularly anti-mullerian hormone levels, in young females after anticancer treatment.
  • PATIENTS AND METHODS: We analysed FSH, LH, estradiol and anti-mullerian hormone (AMH) levels on days 3-5 of a menstrual cycle in thirty three cancer survivors in mean age 19.1+/-4.7 years treated in age 12.0+/-5.6 years for Hodgkin Lymphoma (HL) (n=16), nephroblastoma (n=7), soft tissue sarcoma (n=4), germinal tumor (n=3), neuroblastoma (n=2), histiocytosis (n=1).
  • Particular analysis of all cases showed higher (>2 SD) FSH levels in 8 patients: 5 patients treated for HL with radiotherapy and higher total doses of procarbazine, nitrogen mustard and vinblastine; 2 patients treated for soft tissue sarcoma and one patient for Wilms tumor (all received radiotherapy).
  • Lowered AMH levels were found in 8 patients treated with chemo- and radiotherapy (4 - for HL, 2 - for Wilms tumor and 2 - for soft tissue sarcoma).
  • CONCLUSION: Composed anticancer treatment, especially radiotherapy, leads to ovarian failure.
  • Decreased AMH values at young adulthood suggest a lower ovarian reserve.
  • All causes and first symptoms of ovary damage should be known to the doctors who take care of the patients after anticancer treatment.
  • [MeSH-major] Anti-Mullerian Hormone / metabolism. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Infertility, Female / diagnosis. Menopause, Premature. Primary Ovarian Insufficiency / diagnosis. Radiotherapy / adverse effects
  • [MeSH-minor] Adolescent. Adult. Combined Modality Therapy / adverse effects. Female. Follicle Stimulating Hormone / metabolism. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Humans. Neoplasms / therapy. Ovary / drug effects. Ovary / radiation effects. Survivors


7. Ganjavi H, Gee M, Narendran A, Freedman MH, Malkin D: Adenovirus-mediated p53 gene therapy in pediatric soft-tissue sarcoma cell lines: sensitization to cisplatin and doxorubicin. Cancer Gene Ther; 2005 Apr;12(4):397-406
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenovirus-mediated p53 gene therapy in pediatric soft-tissue sarcoma cell lines: sensitization to cisplatin and doxorubicin.
  • Sarcomas, or tumors of connective tissue, represent roughly 20% of childhood cancers.
  • High-grade or metastatic soft-tissue sarcomas and rhabdomyosarcomas (RMS) of the extremities remain therapeutic challenges and their prognosis is often poor.
  • The future of sarcoma therapy will likely include molecular approaches including gene/protein expression profiling and gene-based therapy.
  • The tumor suppressor p53 is central to regulation of cell growth and tumor suppression and restoring wild-type p53 function in pediatric sarcomas may be of therapeutic benefit.
  • Studies with adenoviral-mediated p53 gene transfer have been conducted in many cancer types including cervical, ovarian, prostatic and head and neck tumors.
  • Using three viral constructs containing cDNA for wild-type p53, mutant p53 (C135S) and lacZ, we studied the effect of adenoviral-mediated gene therapy in four pediatric sarcoma cell lines, RD and Rh4 (RMS), Rh1 (Ewing's sarcoma) and A204 (undifferentiated sarcoma).
  • Using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay, we have shown a dose-dependent decrease in cell viability 72 h post-treatment that occurs with Ad-wtp53 but not with Ad-mutp53.
  • Our results indicate that restoration of wild-type p53 function in pediatric sarcoma cells could provide a basis for novel approaches to treatment of this disease.
  • [MeSH-major] Adenoviridae / genetics. Cisplatin / pharmacology. Doxorubicin / pharmacology. Genes, p53 / genetics. Genetic Therapy / methods
  • [MeSH-minor] Apoptosis. Cell Cycle Proteins / metabolism. Cell Line, Tumor. Cell Proliferation. Cell Survival. Child. Cyclin-Dependent Kinase Inhibitor p21. Dose-Response Relationship, Drug. Gene Transfer Techniques. Humans. In Situ Nick-End Labeling. Mutation. Prognosis. RNA, Messenger / metabolism. Retinoblastoma Protein / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Rhabdomyosarcoma / therapy. Sarcoma / metabolism. Sarcoma / therapy. Tetrazolium Salts / pharmacology. Thiazoles / pharmacology. Time Factors. Tumor Suppressor Protein p53 / metabolism

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15618970.001).
  • [ISSN] 0929-1903
  • [Journal-full-title] Cancer gene therapy
  • [ISO-abbreviation] Cancer Gene Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CDKN1A protein, human; 0 / Cell Cycle Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / RNA, Messenger; 0 / Retinoblastoma Protein; 0 / Tetrazolium Salts; 0 / Thiazoles; 0 / Tumor Suppressor Protein p53; 298-93-1 / thiazolyl blue; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


8. Hamberg P, Verweij J, Sleijfer S: (Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor. Oncologist; 2010;15(6):539-47

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Furthermore, the pazopanib concentration resulting in maximal inhibition of VEGFR-2 phosphorylation in vivo was in line with the steady-state concentration required to inhibit growth of tumor xenografts, suggesting that pazopanib's mechanism of action is indeed through VEGFR-2 inhibition.
  • Administered as monotherapy, evidence of antitumor activity was observed in phase II studies in several tumor types, including soft tissue sarcoma, renal cell cancer (RCC), ovarian cancer, and non-small cell lung cancer.
  • Food and Drug Administration granted approval for treatment with pazopanib in patients with RCC based on the longer progression-free survival time observed with this agent in a placebo-controlled, randomized trial.
  • [MeSH-minor] Animals. Disease-Free Survival. Humans. Neoplasms / blood supply. Neoplasms / drug therapy. Neoplasms / metabolism. Vascular Endothelial Growth Factor Receptor-2 / antagonists & inhibitors. Vascular Endothelial Growth Factor Receptor-2 / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2530-40 [10561319.001]
  • [Cites] J Clin Oncol. 2010 Feb 20;28(6):1061-8 [20100962.001]
  • [Cites] Eur J Cancer. 2002 Mar;38(4):543-9 [11872347.001]
  • [Cites] Lancet Oncol. 2001 Nov;2(11):667-73 [11902537.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):60-5 [12506171.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):327-37 [12538485.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):401-10 [12778130.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7099-109 [15466206.001]
  • [Cites] J Clin Oncol. 2005 Feb 10;23(5):965-72 [15613696.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):25-35 [16314617.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):16-24 [16330672.001]
  • [Cites] JAMA. 2006 Jun 7;295(21):2516-24 [16757724.001]
  • [Cites] Arch Dermatol. 2006 Nov;142(11):1477-9 [17116839.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2542-50 [17167137.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 19;103(51):19478-83 [17164332.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):115-24 [17215529.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):125-34 [17215530.001]
  • [Cites] Curr Oncol Rep. 2007 Mar;9(2):115-9 [17288876.001]
  • [Cites] Mol Cancer Ther. 2007 Jul;6(7):2012-21 [17620431.001]
  • [Cites] Lancet. 2007 Dec 22;370(9605):2103-11 [18156031.001]
  • [Cites] N Engl J Med. 2007 Dec 27;357(26):2666-76 [18160686.001]
  • [Cites] J Clin Oncol. 2008 Nov 20;26(33):5422-8 [18936475.001]
  • [Cites] J Clin Oncol. 2009 Mar 10;27(8):1280-9 [19171708.001]
  • [Cites] Blood. 2009 May 7;113(19):4819-20 [19423744.001]
  • [Cites] Clin Cancer Res. 2009 Jun 15;15(12):4220-7 [19509175.001]
  • [Cites] J Clin Oncol. 2009 Jul 1;27(19):3126-32 [19451427.001]
  • [Cites] Br J Cancer. 2009 Jul 21;101(2):238-43 [19568242.001]
  • [Cites] J Clin Oncol. 2009 Aug 1;27(22):3584-90 [19487381.001]
  • [Cites] J Clin Oncol. 2010 Jan 20;28(3):475-80 [20008644.001]
  • [Cites] Cancer Res. 2001 Jul 15;61(14):5407-14 [11454684.001]
  • (PMID = 20511320.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Pyrimidines; 0 / Sulfonamides; 7RN5DR86CK / pazopanib; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  • [Number-of-references] 37
  • [Other-IDs] NLM/ PMC3227994
  •  go-up   go-down


9. Tejada-Berges T, Granai CO, Gordinier M, Gajewski W: Caelyx/Doxil for the treatment of metastatic ovarian and breast cancer. Expert Rev Anticancer Ther; 2002 Apr;2(2):143-50
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Caelyx/Doxil for the treatment of metastatic ovarian and breast cancer.
  • This, coupled with a small vesicular size, uniquely promotes the localization of Caelyx/Doxil at tumor sites and explains its altered toxicity profile.
  • The FDA and EMEA have approved its use for the treatment of AIDS-related Kaposi's sarcoma and, more recently, for recurrent epithelial ovarian cancer (EOC).
  • Numerous investigations have focused on its use in the treatment of metastatic breast cancer, as well as recurrent squamous cell cervical carcinoma, soft tissue sarcoma, squamous head and neck cancers, prostate cancers and malignant gliomas.
  • Ongoing clinical studies of combination regimens incorporating Caelyx/Doxil will further clarify its role in the treatment of advanced solid tumors.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Breast Neoplasms / drug therapy. Doxorubicin / administration & dosage. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Animals. Clinical Trials as Topic / methods. Clinical Trials as Topic / statistics & numerical data. Female. Humans. Neoplasm Recurrence, Local / drug therapy


10. Ricke J, Sehouli J, Hach C, Hänninen EL, Lichtenegger W, Felix R: Prospective evaluation of contrast-enhanced MRI in the depiction of peritoneal spread in primary or recurrent ovarian cancer. Eur Radiol; 2003 May;13(5):943-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective evaluation of contrast-enhanced MRI in the depiction of peritoneal spread in primary or recurrent ovarian cancer.
  • The purpose of this study was to assess the accuracy of MRI in the staging of intra-abdominal tumor seeding of ovarian carcinoma.
  • Fifty-seven patients with suspected primary or recurrent ovarian carcinoma were included in this study.
  • The MRI protocol included fat-saturated T1-weighted spin-echo (SE) sequences pre- and post i.v. application of gadopentetate dimeglumine.
  • The criteria for tumor manifestation was contrast enhancement of intra-abdominal soft tissue lesions or peritoneum.
  • Laparotomy and histopathology confirmed 251 abdominal tumor locations.
  • Magnetic resonance imaging based on contrast-enhanced fat-saturated T1 SE sequences improves planning of cytoreduction preceding chemotherapy in advanced primary or relapsed ovarian carcinoma.
  • [MeSH-major] Contrast Media. Magnetic Resonance Imaging. Ovarian Neoplasms / pathology. Peritoneal Neoplasms / secondary. Radiographic Image Enhancement
  • [MeSH-minor] Abdominal Neoplasms / diagnosis. Abdominal Neoplasms / secondary. Adult. Aged. Aged, 80 and over. False Positive Reactions. Female. Gastrointestinal Neoplasms / diagnosis. Gastrointestinal Neoplasms / secondary. Genital Neoplasms, Female / diagnosis. Genital Neoplasms, Female / secondary. Humans. Liver Neoplasms / diagnosis. Liver Neoplasms / secondary. Lymphatic Metastasis. Middle Aged. Neoplasm Recurrence, Local. Neoplasms, Second Primary. Pelvic Neoplasms / diagnosis. Pelvic Neoplasms / secondary. Predictive Value of Tests. Prospective Studies. Sensitivity and Specificity. Single-Blind Method. Women's Health

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12695813.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


11. Krawczuk-Rybak M, Leszczyńska E, Zelazowska-Rutkowska B, Wysocka J: [Ovarian function in young women after anticancer treatment in childhood]. Med Wieku Rozwoj; 2008 Oct-Dec;12(4 Pt 2):1028-34
Hazardous Substances Data Bank. MENOTROPINS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ovarian function in young women after anticancer treatment in childhood].
  • AIM: We investigated pituitary-ovarian function in young women after treatment for different cancers in prepubertal and pubertal periods, with or without radiotherapy of infradiaphragmatic areas.
  • PATIENTS AND METHODS: We analyzed the values of follicle-stimulating hormone (FSH) luteinizing hormone (LH), estradiol (E2), inhibin B and anti-müllerian hormone (AMH) in the group of 28 young women aged 18.6 +/- 4.7 years, who had been treated for Hodgkin's Lymphoma HL (n=16), nephroblastoma (n=7), soft tissue sarcoma (n=4), neuroblastoma (n=1).
  • RESULTS: In the whole group the mean levels of FSH, LH and E2 did not differ from the control group, but in the subgroup irradiated infradiaphragmatically FSH concentration was higher than in the control group (8.06+/-3.28 vs 5.8+/-2.03 mIU/ml) p=0.042, particularly after HL treatment (8.53+/-3.25 mIU/ml), p=0.045.
  • We did not observe the influence of age at treatment (prepubertal vs pubertal period) on the values of analyzed hormones.
  • CONCLUSIONS: In young women after anti-cancer treatment, with normal menstrual cycles, the signs of ovarian dysfunction and diminished ovarian reserve are observed.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Ovarian Diseases / etiology. Ovary / drug effects. Ovary / radiation effects. Radiotherapy / adverse effects
  • [MeSH-minor] Adolescent. Anti-Mullerian Hormone / blood. Biomarkers / blood. Child. Estrogens / blood. Female. Follicle Stimulating Hormone / blood. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Humans. Inhibins / blood. Kidney Neoplasms / drug therapy. Kidney Neoplasms / radiotherapy. Neuroblastoma / drug therapy. Neuroblastoma / radiotherapy. Sarcoma / drug therapy. Sarcoma / radiotherapy. Wilms Tumor / drug therapy. Wilms Tumor / radiotherapy

  • MedlinePlus Health Information. consumer health - Ovarian Disorders.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19531821.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers; 0 / Estrogens; 0 / inhibin B; 57285-09-3 / Inhibins; 80497-65-0 / Anti-Mullerian Hormone; 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


12. Medina-Gundrum L, Cerna C, Gomez L, Izbicka E: Investigation of HMN-176 anticancer activity in human tumor specimens in vitro and the effects of HMN-176 on differential gene expression. Invest New Drugs; 2005 Jan;23(1):3-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Investigation of HMN-176 anticancer activity in human tumor specimens in vitro and the effects of HMN-176 on differential gene expression.
  • HMN-176, (E)-4-(2-[2-(N-[4-methoxybenzene-sulfonyl]amino)phenyl]ethenyl) pyridine 1-oxide, is a stilbene derivative which inhibits mitosis without significant effect on tubulin polymerization and displays potent cytotoxicity against a variety of human tumor cell lines.
  • The present study evaluated the activity profile of the antineoplastic agent HMN-176 in an ex-vivo soft agar cloning assay (human tumor colony-forming assay) in a panel of 132 human tumor specimens under 14-day continuous exposure at 0.1, 1.0, and 10.0 microg/ml.
  • Thirty percent of specimens in the different treatment groups (39/132 in 0.1 and 1.0 test groups; 40/132 in 10.0 test group) were assessable, falling within the negative and positive control parameters.
  • HMN-176 demonstrated activity towards 75% of the breast cancer specimens (6/8) treated with 1.0 microg/ml, 67% of non small-cell lung (4/6) and 57% of ovarian (4/7) cancer specimens treated with 10 microg/ml.
  • Evaluation of differential gene expression in drug-sensitive (A2780) and drug-resistant (A2780cp) ovarian carcinoma cell lines exposed to 0.1 microg/ml HMN-176 up to 48 h using cDNA microarrays with 1,154 known human genes revealed significant drug effects on tumor associated genes, including upregulation of tissue inhibitor matrix metalloproteinases gene (TIMP) in both cell lines, suggesting that HMN-176 could potentially overcome tumor drug resistance.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Benzylidene Compounds / pharmacology. Gene Expression Regulation, Neoplastic / drug effects. Neoplasms / drug therapy. Pyridines / pharmacology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Colony-Forming Units Assay. Gene Expression Profiling. Humans. In Vitro Techniques. Oligonucleotide Array Sequence Analysis. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cell Cloning. 1987 Mar;5(2):170-8 [3106514.001]
  • [Cites] Cancer Res. 2003 Oct 15;63(20):6942-7 [14583495.001]
  • [Cites] Anticancer Drugs. 1999 Mar;10(3):295-302 [10327036.001]
  • [Cites] Curr Cancer Drug Targets. 2002 Sep;2(3):257-77 [12188911.001]
  • [Cites] Int J Oncol. 2000 Oct;17(4):673-81 [10995877.001]
  • [Cites] Ann Oncol. 1999 Apr;10 (4):449-53 [10370788.001]
  • [Cites] J Clin Oncol. 1986 Dec;4(12):1730-1 [3783200.001]
  • [Cites] J Natl Cancer Inst. 1990 Jan 17;82(2):96-101 [2403594.001]
  • [Cites] Cancer Res. 1983 Apr;43(4):1926-31 [6339044.001]
  • [Cites] Anticancer Drugs. 1992 Apr;3(2):121-4 [1356030.001]
  • [Cites] Anticancer Drugs. 1997 Apr;8(4):379-85 [9180392.001]
  • [Cites] Anticancer Drugs. 1999 Mar;10(3):303-7 [10327037.001]
  • [Cites] Cancer Res. 1985 May;45(5):2145-53 [3986767.001]
  • [Cites] Cancer Treat Rep. 1986 Dec;70(12):1379-82 [3791251.001]
  • [Cites] Invest New Drugs. 2003 Nov;21(4):387-99 [14586206.001]
  • [Cites] Am J Med. 1981 May;70(5):1027-41 [7234870.001]
  • [Cites] Science. 1977 Jul 29;197(4302):461-3 [560061.001]
  • [Cites] Yao Xue Xue Bao. 2003 Jul;38(7):501-4 [14515793.001]
  • [Cites] J Natl Cancer Inst. 1994 Jan 5;86(1):30-3 [8271279.001]
  • (PMID = 15528975.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / (E)-4-((2-N-(4-methoxybenzenesulfonyl)amino)stilbazole)1-oxide; 0 / Antineoplastic Agents; 0 / Benzylidene Compounds; 0 / Biomarkers, Tumor; 0 / Pyridines
  •  go-up   go-down


13. D'Incalci M, Colombo T, Ubezio P, Nicoletti I, Giavazzi R, Erba E, Ferrarese L, Meco D, Riccardi R, Sessa C, Cavallini E, Jimeno J, Faircloth GT: The combination of yondelis and cisplatin is synergistic against human tumor xenografts. Eur J Cancer; 2003 Sep;39(13):1920-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The combination of yondelis and cisplatin is synergistic against human tumor xenografts.
  • Yondelis (trabectidin, ET-743) is a marine natural product that has shown activity both in preclinical systems and in human malignancies such as soft tissue sarcoma and ovarian cancers that are resistant to previous chemotherapies.
  • Molecular pharmacological studies indicated that Yondelis interacts with DNA and DNA repair systems in a way that is different from Cisplatin (DDP).
  • The in vitro studies performed in human TE-671 rhabdomyosarcoma, Igrov-1 and 1A9 human ovarian carcinoma cell lines showed additive effects or slight synergism.
  • Several human tumour xenografts, such as TE-671 rhabdomyosarcoma, SK-N-DX neuroblastoma, FADU head and neck, LX-1 non-small cell lung cancer (NSCLC), H-187 melanoma and SKOV HOC 8 ovarian carcinoma, showed an antitumour effect for the combination that was greater than that of each drug when given as a single agent.
  • An orthotopically transplanted human ovarian cancer HOC 8 growing in the peritoneal cavity of nude mice was used that is insensitive to Yondelis alone and only moderately sensitive to DDP alone.
  • The combination of the two drugs produced a dramatic increase of survival lasting several months.
  • In conclusion, the combination of Yondelis and DDP is synergistic in vivo (i.e. the antitumour effect is greater than that of each drug used as a single agent at the maximum tolerated dose (MTD)) in different human tumour xenografts.
  • The two drugs can be combined at the MTD of each drug, thus indicating there are no overlapping toxicities.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / drug therapy. Rhabdomyosarcoma / drug therapy
  • [MeSH-minor] Animals. Cisplatin / administration & dosage. Cisplatin / adverse effects. Dioxoles / administration & dosage. Dioxoles / adverse effects. Drug Synergism. Female. Humans. Isoquinolines / administration & dosage. Isoquinolines / adverse effects. Mice. Neoplasm Transplantation. Tetrahydroisoquinolines. Transplantation, Heterologous. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Cancer. 2003 Sep;39(13):1816-7 [12932657.001]
  • (PMID = 12932672.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Dioxoles; 0 / Isoquinolines; 0 / Tetrahydroisoquinolines; 114899-77-3 / trabectedin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


14. Siva Prasad G, Chacko KN, Antony D, Lionel G, Kekre NS, Gopalakrishnan G: Bladder-sparing surgery in locally advanced nonurological pelvic malignancy. Urol Int; 2006;77(1):18-21
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Often a dilemma exists between cystectomy and a bladder-sparing procedure.
  • 10 had locally advanced colorectal malignancy, 3 with soft tissue masses of the lateral pelvic wall, 1 had ovarian malignancy and the other had residual mass following radiotherapy and chemotherapy of cancer cervix.
  • Palliative transurethral resection was done in 1 patient with tumor infiltration at the bladder neck and prostate.
  • Preoperative CT scan or MRI can predict lower urinary tract involvement and help in decision-making by both surgeon and patient.
  • The ultimate decision for bladder sparing is based on intraoperative findings.
  • [MeSH-major] Colorectal Neoplasms / surgery. Ovarian Neoplasms / surgery. Soft Tissue Neoplasms / surgery. Uterine Cervical Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16825810.001).
  • [ISSN] 0042-1138
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


15. Dilek TU, Dilek S, Pata O, Tataroglu C, Tok E: Malignant fibrous histiocytoma of the ovary: a case report. Int J Gynecol Cancer; 2006 Jan-Feb;16 Suppl 1:352-6
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant fibrous histiocytoma of the ovary: a case report.
  • Malignant fibrous histiocytoma is the most common type of soft tissue sarcoma in adults.
  • Primary malignant fibrous histiocytoma of the ovary is extremely rare, with only three previously reported cases.
  • She was referred for adjuvant chemotherapy to our center with the diagnosis of storiform-pleomorphic malignant fibrous histiocytoma.
  • A left adnexal mass was detected by computed tomography of the lower abdomen.
  • Resection of all macroscopic disease is independently associated with improved disease-specific survival, and adjuvant chemotherapy for nonmyxoid variants could be acceptable alternatives if the surgical margins are tumor free.
  • [MeSH-major] Histiocytoma, Malignant Fibrous / surgery. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Cyclophosphamide / therapeutic use. Female. Humans. Reoperation

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515621.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


16. Dey S: Biricodar. Vertex Pharmaceuticals. Curr Opin Investig Drugs; 2002 May;3(5):818-23
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Vertex is developing biricodar as a chemosensitizing agent designed to restore the effectiveness of chemotherapeutic agents in tumor multidrug resistance.
  • By November 1998, phase II trials had commenced for biricodar, in combination with chemotherapy, for five common cancer indications: breast, ovarian, soft-tissue sarcomas, small cell lung cancer and prostate cancer.
  • Vertex has published three patents, WO-09615101, WO-09636630 and WO-09736869, disclosing derivatives of biricodar that are claimed for the treatment of multidrug resistant protein and P-glycoprotein-mediated multidrug resistant tumors.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Piperidines / therapeutic use. Pyridines / therapeutic use
  • [MeSH-minor] Clinical Trials as Topic. Drug Resistance, Multiple. Drug Resistance, Neoplasm. Humans. Neoplasms / drug therapy. Structure-Activity Relationship

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12090559.001).
  • [ISSN] 1472-4472
  • [Journal-full-title] Current opinion in investigational drugs (London, England : 2000)
  • [ISO-abbreviation] Curr Opin Investig Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Piperidines; 0 / Pyridines; 3KG76X4KJK / biricodar
  • [Number-of-references] 50
  •  go-up   go-down


17. Tokunaga Y, Hosogi H, Nakagami M, Tokuka A, Ohsumi K: A case of chest wall recurrence of breast cancer treated with paclitaxel weekly, 5'-deoxy-5-fluorouridine, arterial embolization and chest wall resection. Breast Cancer; 2003;10(4):366-70
Hazardous Substances Data Bank. FLOXURIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chest wall resection and reconstruction has proved to be a safe surgical procedure for local recurrence of breast cancer.
  • Recently, as second- or third-line chemotherapy for the patients with recurrent breast cancer or ovarian cancer, weekly paclitaxel has provided a significant response rate in those patients, and generated much clinical interest.
  • A recurrent tumor developed and enlarged one-and-half years after undergoing modified radical mastectomy for advanced breast cancer (T4N2M0, stage III B) at another hospital.
  • The mass had enlarged while the patient underwent chemotherapy with cyclophosphamide, doxorubicin, 5-fluorouracil, and anastozole, followed by low-dose cisplatin, 5-fluorouracil, and goserelin.
  • Chest wall resection, reconstruction of the bony chest wall with polypropylene mesh folded 8 times, and soft tissue reconstruction with a contralateral myocutaneous flap were carried out successfully.
  • A multimodal approach with chemotherapy and arterial embolization was effective in this case in treating chest wall recurrence of breast cancer.
  • Reconstruction of the chest wall bone with polypropylene mesh folded 8 times and soft tissue reconstruction with a contralateral myocutaneous flap was a useful procedure after chest wall resection, even after chemotherapy and arterial embolization.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / therapy. Carcinoma, Ductal / therapy. Embolization, Therapeutic. Reconstructive Surgical Procedures / methods. Thoracic Wall
  • [MeSH-minor] Angiography. Female. Floxuridine / administration & dosage. Humans. Middle Aged. Paclitaxel / administration & dosage. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14634517.001).
  • [ISSN] 1340-6868
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 039LU44I5M / Floxuridine; P88XT4IS4D / Paclitaxel; V1JK16Y2JP / doxifluridine
  •  go-up   go-down


18. Chow E, Merchant TE, Pappo A, Jenkins JJ, Shah AB, Kun LE: Cutaneous and subcutaneous Ewing's sarcoma: an indolent disease. Int J Radiat Oncol Biol Phys; 2000 Jan 15;46(2):433-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The occurrence of extraosseous Ewing's sarcoma (ES) in deep soft tissues has been well described, but cases in which this tumor occurs in a primary cutaneous or subcutaneous site have rarely been reported.
  • The superficial variant may be less aggressive than are the more common bony and deep soft tissue counterparts with an apparently favorable outcome.
  • Thirteen had definitive surgical resections, and one had biopsy of the mass at the time of referral.
  • All patients received chemotherapy, composed of vincristine, doxorubicin, cyclophosphamide, ifosfamide, etoposide, and dactinomycin.
  • Patients on institutional protocols received radiation (36 Gy) to the operative bed (150-180 cGy/fraction/day).
  • Thirteen patients had wide local excision of the primary tumors prior to enrollment on chemotherapy; surgical margins were negative (10), microscopically positive (2), and indeterminate (1).
  • Eleven patients received radiotherapy to the tumor bed; 2 with clear surgical margins were treated without irradiation.
  • The patient who had biopsy only received induction chemotherapy followed by definitive surgical resection and postoperative radiotherapy.
  • None of the patients has developed local recurrence or distant metastasis.
  • Several of the patients developed treatment-related sequelae, including veno-occlusive disease of the lung and hemorrhagic cystitis (1), myelodysplastic syndrome (1), chemotherapy-induced ovarian failure (1), moist desquamation (1), and dermatofibroma within the radiotherapy volumes (1).
  • CONCLUSIONS: Cutaneous and subcutaneous ES are associated with an indolent course and a favorable prognosis when treated with combined modality therapy.
  • Elimination of radiation therapy following complete resection has been tested in the POG 9354 trial.
  • The high rate of local control, low rate of metastatic disease, and excellent overall outcome may suggest a role for less intensive chemotherapy, as well as tailoring to diminish or avoid radiation therapy in completely resected cases, with a goal to minimize toxicity while maintaining a high cure rate.
  • [MeSH-minor] Adolescent. Adult. Child. Combined Modality Therapy. Female. Humans. Male. Retrospective Studies

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10661351.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA 21765
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  •  go-up   go-down


19. Rossi CR, Mocellin S, Pilati P, Foletto M, Quintieri L, Palatini P, Lise M: Pharmacokinetics of intraperitoneal cisplatin and doxorubicin. Surg Oncol Clin N Am; 2003 Jul;12(3):781-94
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intraperitoneal chemotherapy, mainly when performed during HIIC after cytoreductive surgery, is considered potentially curative for the treatment of solid tumors with spread to the peritoneal surface.
  • When selecting antiblastic agents to be administered intraperitoneally, it is important to bear in mind that a low lipophility and a high molecular weight are the ideal drug characteristics.
  • Drugs with these features allow a favorable ratio to be achieved between peritoneal and plasma concentrations, due to the reduced tendency to diffuse through the plasma-peritoneal barrier, even after extensive removal of the peritoneum.
  • Moreover, a low rate of diffusion through the tumor capillaries implies a low rate of drug clearance, with a higher intratumoral drug accumulation.
  • Among the drugs used so far for intraperitoneal chemotherapy, the combination of CDDP and DXR appears to be one of the most effective available regimens with acceptable local-regional toxicity.
  • CDDP has also been extensively employed as a single agent for ovarian and gastrointestinal cancers, under both normal and hyperthermic conditions, while intraperitoneally administered DXR appears to be of greater potential efficacy when associated with CDDP and hyperthermia (41.5 degrees C) following cytoreductive surgery.
  • In our clinical experience with this drug combination, DXR showed a much more advantageous plasma/peritoneal AUC ratio than CDDP (162 +/- 113 and 20 +/- 6, respectively).
  • Penetration of the tumor mass by CDDP is greater than DXR.
  • Following experimental and clinical results of TNF alpha-based isolated limb perfusion for locally advanced soft tissue sarcoma or melanoma, greater efforts are being made to exploit the potential effect of this cytokine used in association with hyperthermia and other drugs (i.e., CDDP and DXR) suitable for intraperitoneal infusion/perfusion.
  • However, it is not yet clear whether the observed effect of TNF alpha on the peritoneal-plasma barrier, which seems to favor the passage of both drugs into the systemic circulation, is overcome by the positive effect of this agent on drug penetration into tumor.
  • Further pharmacologic studies should be undertaken to clarify whether or not these interactions will be of benefit to the patient.
  • Likewise, liposomes, which in animal models seem to favor tumor uptake of encapsulated DXR, should now be tested in the clinical setting.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / pharmacokinetics. Carcinoma / drug therapy. Infusions, Parenteral. Peritoneal Neoplasms / drug therapy
  • [MeSH-minor] Biological Availability. Cisplatin / administration & dosage. Combined Modality Therapy. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Female. Humans. Intraoperative Period. Male. Maximum Tolerated Dose. Neoplasm Staging. Peritoneum / drug effects. Peritoneum / surgery. Prognosis. Randomized Controlled Trials as Topic. Risk Assessment. Survival Rate. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14567031.001).
  • [ISSN] 1055-3207
  • [Journal-full-title] Surgical oncology clinics of North America
  • [ISO-abbreviation] Surg. Oncol. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 50
  •  go-up   go-down


20. LaPlant KD, Louzon PD: Pazopanib: an oral multitargeted tyrosine kinase inhibitor for use in renal cell carcinoma. Ann Pharmacother; 2010 Jun;44(6):1054-60
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To summarize the currently available clinical data on pazopanib, as well as review the merits and adverse effects of pazopanib in the treatment of renal cell carcinoma (RCC).
  • Phase 2 and 3 studies have shown promising activity in RCC, including treatment naïve or cytokine-pretreated patients, demonstrating a greater rate of total disease control with pazopanib compared to placebo.
  • Activity has also been shown in a variety of other cancers, including ovarian cancer, non-small-cell lung cancer, breast cancer, and soft tissue sarcoma.
  • Other Phase 3 trials are ongoing in RCC, including a comparison to sunitinib, another TKI used in RCC, as well as trials in other tumor types.
  • CONCLUSIONS: Current data suggest pazopanib to be a viable treatment option as first-line therapy for advanced RCC.
  • Until results of head-to-head trials conducted of the various agents are available, it cannot be said whether pazopanib is more tolerable or efficacious than currently available therapies.
  • [MeSH-major] Carcinoma, Renal Cell / drug therapy. Drug Delivery Systems / methods. Kidney Neoplasms / drug therapy. Protein Kinase Inhibitors / administration & dosage. Protein-Tyrosine Kinases / antagonists & inhibitors. Pyrimidines / administration & dosage. Sulfonamides / administration & dosage

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20407031.001).
  • [ISSN] 1542-6270
  • [Journal-full-title] The Annals of pharmacotherapy
  • [ISO-abbreviation] Ann Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / Sulfonamides; 7RN5DR86CK / pazopanib; EC 2.7.10.1 / Protein-Tyrosine Kinases
  • [Number-of-references] 36
  •  go-up   go-down


21. Corbett TH, White K, Polin L, Kushner J, Paluch J, Shih C, Grossman CS: Discovery and preclinical antitumor efficacy evaluations of LY32262 and LY33169. Invest New Drugs; 2003 Feb;21(1):33-45
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For this discovery, a disk-diffusion-soft-agar-colony-formation-assay was used to screen a portion of the Eli Lilly inventory, with the evaluation of each agent against normal cells, leukemic cells and several solid tumors, including a multidrug-resistant solid tumor (with marked selective cytotoxicity for Colon-38 and Human-Colon-15/MDR compared to normal fibroblasts and L1210 leukemic cells characterizing the discovery).
  • In addition, many other tumors were highly sensitive: Panc-03 = 2.4 log kill (LK); Panc-02 = 2.9-4.1 LK; Squamous Lung LC-12 = 2.1 LK; Colon-26 = 2.2 LK; AML1498 = 2.7 LK; Human Sm Cell Lung DMS-273 = 6.3 LK; Human Squamous Lung 165 = 3.7 LK; Human Ovarian BG-1 = 3.7 LK; Human Colon CX-1 (H29) = 1.6 LK; Human Colon-15/MDR (a p-glycoprotein positive multidrug resistant tumor) = 2.3 LK; Human CNS-gliosarcoma-SF295 = 3.8 LK.
  • There was no absolute tissue of origin correlation with antitumor efficacy, although colon tumors were most responsive and mammary tumors least responsive.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzamides / therapeutic use. Neoplasms, Experimental / drug therapy. Sulfonamides / therapeutic use
  • [MeSH-minor] Administration, Oral. Animals. Anti-Bacterial Agents / chemistry. Anti-Bacterial Agents / therapeutic use. Anti-Bacterial Agents / toxicity. Dose-Response Relationship, Drug. Drug Resistance, Multiple. Drug Resistance, Neoplasm. Drug Stability. Humans. Injections, Intravenous. Mice. Pharmaceutical Solutions. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 1949 Aug;10(1):179-92 [18143260.001]
  • [Cites] Invest New Drugs. 1989 Apr;7(1):37-49 [2661481.001]
  • [Cites] Prog Clin Biol Res. 1980;37:115-32 [7384082.001]
  • [Cites] Cancer Res. 1984 Feb;44(2):717-26 [6692374.001]
  • [Cites] Invest New Drugs. 1998;16(2):129-39 [9848576.001]
  • [Cites] J Exp Ther Oncol. 1996 Mar;1(2):95-108 [9414393.001]
  • [Cites] Cancer Treat Rep. 1979 Sep-Oct;63(9-10):1459-73 [291480.001]
  • [Cites] Cancer. 1989 Jan 15;63(2):280-8 [2910432.001]
  • [Cites] Cancer Res. 1990 Aug 15;50(16):4900-5 [2165850.001]
  • [Cites] Cancer Res. 1966 Apr;26(4 Pt 2):375-90 [4223140.001]
  • [Cites] Cancer. 1980 Mar 1;45(5):906-18 [6266631.001]
  • [Cites] Cancer Res. 1990 Jul 15;50(14):4360-5 [1973071.001]
  • [Cites] Invest New Drugs. 1987;5(1):3-20 [3298130.001]
  • [Cites] Cancer Res. 1986 Feb;46(2):798-806 [3940644.001]
  • [Cites] Cancer Res. 1986 Nov;46(11):5893-902 [3019542.001]
  • [Cites] Cancer Lett. 1985 Sep 15;28(2):187-93 [3863701.001]
  • [Cites] Invest New Drugs. 1997;15(2):99-108 [9220288.001]
  • [Cites] Cancer Res. 1975 Sep;35(9):2434-9 [1149045.001]
  • [Cites] Environ Res. 1972 Jun;5(2):152-63 [5036961.001]
  • [Cites] Cancer Treat Rep. 1978 Oct;62(10):1471-88 [709550.001]
  • [Cites] Invest New Drugs. 1999;17(1):17-27 [10555119.001]
  • [Cites] Cancer Treat Rep. 1983 Oct;67(10):905-22 [6354439.001]
  • [Cites] Cancer. 1977 Nov;40(5 Suppl):2660-80 [922705.001]
  • [Cites] Cancer Res. 1981 May;41(5):1751-6 [7214343.001]
  • [Cites] Invest New Drugs. 1988 Dec;6(4):259-64 [3068184.001]
  • [Cites] Cancer Res. 1979 Mar;39(3):1020-5 [427742.001]
  • [Cites] Invest New Drugs. 1997;15(3):207-18 [9387043.001]
  • [Cites] J Clin Invest. 1995 May;95(5):2205-14 [7738186.001]
  • [Cites] Prog Clin Biol Res. 1980;37:85-109 [6155671.001]
  • [Cites] Cancer Res. 1982 May;42(5):1707-15 [7066891.001]
  • (PMID = 12795528.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA46560
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antineoplastic Agents; 0 / Benzamides; 0 / N-(2,4-dichlorobenzoyl)-4-chlorophenylsulfonamide; 0 / N-(2,4-dichlorobenzoyl)phenylsulfonamide; 0 / Pharmaceutical Solutions; 0 / Sulfonamides
  •  go-up   go-down


22. Cai X, Gray PJ Jr, Von Hoff DD: DNA minor groove binders: back in the groove. Cancer Treat Rev; 2009 Aug;35(5):437-50
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • With recent approval of the minor groove binding agent trabectidin in Europe for the treatment of patients with soft tissue sarcomas, there has been renewed interest in minor groove binders.
  • These agents have demonstrable anti-tumor activity against a wide variety of tumor types including leukemias, sarcomas, melanomas, breast and ovarian cancers.
  • Applying these agents according to a particular tumor's context of vulnerability might reveal previously unconsidered applications for this diverse class of agents.
  • This review provides a look at how minor groove binding agents have progressed from the lab through the clinic with particular emphasis on identifying the contexts of vulnerabilities of patient tumors which increase the effectiveness of these drugs.
  • [MeSH-major] Antineoplastic Agents / chemistry. Antineoplastic Agents / pharmacology. DNA / drug effects. Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19328629.001).
  • [ISSN] 1532-1967
  • [Journal-full-title] Cancer treatment reviews
  • [ISO-abbreviation] Cancer Treat. Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 9007-49-2 / DNA
  • [Number-of-references] 97
  •  go-up   go-down


23. Mikuz G: [WHO classification of testicular tumors]. Verh Dtsch Ges Pathol; 2002;86:67-75
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Such atypical cells appear in the tubules adjacent to the germ cell tumors, in some few cases (6%) also in the contra lateral healthy gonad and rarely in infertile men (1%).
  • The precursor lesion can progress to franc germ cell tumor starting probably with seminoma, which still maintain the capability of differentiation (pluripotente cells) in all other types of non-seminomatous germ cell tumors.
  • This is a harmless name for an extremely dangerous tumor in which one tissue overgrows the other and gives rise to somatic type sarcomas or carcinomas.
  • Such tumors do not respond like germ cell tumors to the usual chemotherapy.
  • Treatment should be tailored according to that used in standard management of the respective sarcoma or carcinoma.
  • In the comments it is mentioned that the testis carcinoid could be a part of teratoma, but the diagnosis is listed in the group of "miscellaneous" tumors together with tumors of ovarian epithelial type.
  • This is a very questionable decision because the normal testis does not contain neuroendocrine cells from which carcinoids would have to be able to develop.
  • This morphologically peculiar tumor can be part of the Swiss syndrome also called Carney's complex.
  • The patients have cardiac myxomas, spotty skin pigmentation, hormone active nodular hyperplasia of the adrenals and soft tissue myxomas.
  • For the therapy of germ cell tumor an assessment of risk factors found by the pathologists is extremely important.
  • The most important independent predictors of relapse are tumor invasion of blood or lymph-vessels, absence of yolk sac elements and the presence of an embryonal carcinoma component.
  • In the absence of such predictors a surveillance policy allows some patients to forgo chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12647353.001).
  • [ISSN] 0070-4113
  • [Journal-full-title] Verhandlungen der Deutschen Gesellschaft für Pathologie
  • [ISO-abbreviation] Verh Dtsch Ges Pathol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 48
  •  go-up   go-down


24. Cuevas C, Francesch A: Development of Yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problem. Nat Prod Rep; 2009 Mar;26(3):322-37
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Their potent antiproliferative activity against a variety of tumor cells makes them attractive candidates for development as anticancer agents.
  • The lead compound, Yondelis (trabectedin, ET-743) is the first marine anticancer agent approved in the European Union for patients with soft tissue sarcoma (STS).
  • Positive results of a large randomized Phase III clinical trial in ovarian cancer have recently been presented.
  • [MeSH-major] Antineoplastic Agents, Alkylating / chemical synthesis. Antineoplastic Agents, Alkylating / pharmacology. Dioxoles / chemical synthesis. Dioxoles / pharmacology. Ovarian Neoplasms / drug therapy. Tetrahydroisoquinolines / chemical synthesis. Tetrahydroisoquinolines / pharmacology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19240944.001).
  • [ISSN] 0265-0568
  • [Journal-full-title] Natural product reports
  • [ISO-abbreviation] Nat Prod Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Dioxoles; 0 / Tetrahydroisoquinolines; 114899-77-3 / trabectedin
  • [Number-of-references] 72
  •  go-up   go-down


25. Akçay MN: Metastatic disease in the breast. Breast; 2002 Dec;11(6):526-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of solid tumors at other sites, the most common cancers to metastasize to the breast are, in declining order of frequency, malignant melanoma, lymphoma, lung cancer, ovarian carcinoma, soft tissue sarcoma, and gastrointestinal and genitourinary tumors.
  • Lesions that metastasize to the breast may produce changes that look similar to those of primary breast cancer on mammography, but they are more likely to be multiple, are frequently bilateral, and form a nidus of tumor cells that are usually round with fairly well-defined margins.
  • In recent reports, particular importance has been attached to the performance of fine-needle aspiration cytology diagnosis, to differentiate a metastasis from a second primary tumor, thus making it possible to avoid unnecessary mastectomy and ensure that appropriate chemotherapy and radiotherapy are implemented.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14965721.001).
  • [ISSN] 0960-9776
  • [Journal-full-title] Breast (Edinburgh, Scotland)
  • [ISO-abbreviation] Breast
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


26. Newman S: Eribulin, a simplified ketone analog of the tubulin inhibitor halichondrin B, for the potential treatment of cancer. Curr Opin Investig Drugs; 2007 Dec;8(12):1057-66
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eribulin, a simplified ketone analog of the tubulin inhibitor halichondrin B, for the potential treatment of cancer.
  • Eisai Co Ltd is developing eribulin, a simplified synthetic macrocyclic ketone analog of the tubulin inhibitor halichondrin B, for the potential treatment of cancer.
  • Eribulin is currently in phase II trials for NSCLC and soft tissue sarcoma, and pancreatic, prostate, ovarian, fallopian tube, peritoneal and head and neck cancer, and phase I/II trials for urothelial cancers.
  • [MeSH-major] Antineoplastic Agents. Ethers, Cyclic / antagonists & inhibitors. Furans / therapeutic use. Ketones / chemistry. Neoplasms / drug therapy. Tubulin Modulators / antagonists & inhibitors
  • [MeSH-minor] Alopecia / chemically induced. Animals. Apoptosis / drug effects. Cell Line. Cell Line, Tumor. Clinical Trials, Phase I as Topic. Clinical Trials, Phase II as Topic. Clinical Trials, Phase III as Topic. Drug Evaluation, Preclinical. Fatigue / chemically induced. Humans. Hypoglycemia / chemically induced. Hypophosphatemia / chemically induced. Inhibitory Concentration 50. Macrolides. Molecular Structure. Multicenter Studies as Topic. Nausea / chemically induced. Neutropenia / chemically induced. Peripheral Nervous System Diseases / chemically induced. Randomized Controlled Trials as Topic. Survival Analysis. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18058576.001).
  • [ISSN] 1472-4472
  • [Journal-full-title] Current opinion in investigational drugs (London, England : 2000)
  • [ISO-abbreviation] Curr Opin Investig Drugs
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Ethers, Cyclic; 0 / Furans; 0 / Ketones; 0 / Macrolides; 0 / Tubulin Modulators; 0 / eribulin; 103614-76-2 / halichondrin B
  •  go-up   go-down


27. Daghir A, Anand P, Gabra H, Elliot D: Drug-induced exacerbation of glomus tumour pain. J Hand Surg Br; 2006 Dec;31(6):692
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Drug-induced exacerbation of glomus tumour pain.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / adverse effects. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Glomus Tumor / surgery. Neoplasms, Multiple Primary / surgery. Ovarian Neoplasms / drug therapy. Paclitaxel / adverse effects. Pain, Postoperative / chemically induced. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Carboplatin / administration & dosage. Carboplatin / adverse effects. Chemotherapy, Adjuvant. Female. Humans. Middle Aged. Reoperation

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16766103.001).
  • [ISSN] 0266-7681
  • [Journal-full-title] Journal of hand surgery (Edinburgh, Scotland)
  • [ISO-abbreviation] J Hand Surg Br
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down






Advertisement